Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions
AVTE Stock Forecast
Aerovate Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 388.72% upside from AVTE’s last price of $2.66) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
AVTE Price Target
AVTE Analyst Ratings
Hold
Aerovate Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 17, 2024 | Liisa Bayko | Evercore ISI | $2.00 | $1.65 | 21.21% | -24.81% |
Jun 17, 2024 | Eun Yang | Jefferies | $2.00 | $1.65 | 21.21% | -24.81% |
Apr 01, 2024 | Tiago Fauth | Wells Fargo | $35.00 | $29.57 | 18.36% | 1215.79% |
Mar 25, 2024 | Eun Yang | Jefferies | $65.00 | $26.95 | 141.19% | 2343.61% |
10
Aerovate Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $26.00 |
Last Closing Price | $2.66 | $2.66 | $2.66 |
Upside/Downside | -100.00% | -100.00% | 877.44% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jun 18, 2024 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
Jun 17, 2024 | Cowen & Co. | - | Hold | Downgrade |
Jun 17, 2024 | Guggenheim | - | Neutral | Downgrade |
Jun 17, 2024 | Jefferies | - | Hold | Downgrade |
Jun 17, 2024 | BTIG | Buy | Neutral | Downgrade |
Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Dec 06, 2022 | BTIG | - | Buy | Upgrade |
10
Aerovate Therapeutics Financial Forecast
Aerovate Therapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
High Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
Low Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Aerovate Therapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Aerovate Therapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-17.74M | $-16.54M | $-15.76M | $-21.08M | $-3.46M | $-5.20M | $-7.07M | $-8.51M | $-11.62M | $-16.16M | $-23.65M |
High Forecast | $-17.74M | $-16.54M | $-15.76M | $-21.08M | $-3.46M | $-5.20M | $-7.07M | $-5.11M | $-5.52M | $-16.16M | $-23.65M |
Low Forecast | $-17.74M | $-16.54M | $-15.76M | $-21.08M | $-3.46M | $-5.20M | $-7.07M | $-11.64M | $-17.43M | $-16.16M | $-23.65M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Aerovate Therapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Aerovate Therapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.12 | $-0.18 | $-0.24 | $-0.29 | $-0.40 | $-0.56 | $-0.82 |
High Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.12 | $-0.18 | $-0.24 | $-0.18 | $-0.19 | $-0.56 | $-0.82 |
Low Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.12 | $-0.18 | $-0.24 | $-0.40 | $-0.60 | $-0.56 | $-0.82 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Aerovate Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ANTX | AN2 Therapeutics | $1.30 | $8.75 | 573.08% | Buy |
AVTE | Aerovate Therapeutics | $2.66 | $13.00 | 388.72% | Hold |
OPT | Opthea | $3.28 | $14.00 | 326.83% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
ACRV | Acrivon Therapeutics | $6.50 | $21.83 | 235.85% | Buy |
RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
ADAG | Adagene | $2.09 | $5.00 | 139.23% | Buy |
MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |